230 related articles for article (PubMed ID: 37397523)
1. Niclosamide (NA) overcomes cisplatin resistance in human ovarian cancer.
Huang L; Zhang J; Deng Y; Wang H; Zhao P; Zhao G; Zeng W; Wang Y; Chen C; Wagstaff W; Haydon RC; Reid RR; He TC; Shen L; Luu HH; Zhao L
Genes Dis; 2023 Jul; 10(4):1687-1701. PubMed ID: 37397523
[TBL] [Abstract][Full Text] [Related]
2. Antiparasitic mebendazole (MBZ) effectively overcomes cisplatin resistance in human ovarian cancer cells by inhibiting multiple cancer-associated signaling pathways.
Huang L; Zhao L; Zhang J; He F; Wang H; Liu Q; Shi D; Ni N; Wagstaff W; Chen C; Reid RR; Haydon RC; Luu HH; Shen L; He TC; Tang L
Aging (Albany NY); 2021 Jul; 13(13):17407-17427. PubMed ID: 34232919
[TBL] [Abstract][Full Text] [Related]
3. A Blockade of IGF Signaling Sensitizes Human Ovarian Cancer Cells to the Anthelmintic Niclosamide-Induced Anti-Proliferative and Anticancer Activities.
Deng Y; Wang Z; Zhang F; Qiao M; Yan Z; Wei Q; Wang J; Liu H; Fan J; Zou Y; Liao J; Hu X; Chen L; Yu X; Haydon RC; Luu HH; Qi H; He TC; Zhang J
Cell Physiol Biochem; 2016; 39(3):871-88. PubMed ID: 27497986
[TBL] [Abstract][Full Text] [Related]
4. Combination of Niraparib, Cisplatin and Twist Knockdown in Cisplatin-Resistant Ovarian Cancer Cells Potentially Enhances Synthetic Lethality through ER-Stress Mediated Mitochondrial Apoptosis Pathway.
Bahar E; Kim JY; Kim DC; Kim HS; Yoon H
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920140
[TBL] [Abstract][Full Text] [Related]
5. Exosome-liposome hybrid nanoparticle codelivery of TP and miR497 conspicuously overcomes chemoresistant ovarian cancer.
Li L; He D; Guo Q; Zhang Z; Ru D; Wang L; Gong K; Liu F; Duan Y; Li H
J Nanobiotechnology; 2022 Jan; 20(1):50. PubMed ID: 35078498
[TBL] [Abstract][Full Text] [Related]
6. MicroRNAs as the critical regulators of Cisplatin resistance in ovarian cancer cells.
Moghbeli M
J Ovarian Res; 2021 Sep; 14(1):127. PubMed ID: 34593006
[TBL] [Abstract][Full Text] [Related]
7. Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer.
Liu J; Chen X; Ward T; Pegram M; Shen K
Tumour Biol; 2016 Jul; 37(7):9825-35. PubMed ID: 26810188
[TBL] [Abstract][Full Text] [Related]
8. LncRNA WDFY3-AS2 promotes cisplatin resistance and the cancer stem cell in ovarian cancer by regulating hsa-miR-139-5p/SDC4 axis.
Wu Y; Wang T; Xia L; Zhang M
Cancer Cell Int; 2021 May; 21(1):284. PubMed ID: 34051810
[TBL] [Abstract][Full Text] [Related]
9. Anlotinib Exerts Inhibitory Effects against Cisplatin-Resistant Ovarian Cancer In Vitro and In Vivo.
Ji Y; Li X; Qi Y; Zhao J; Zhang W; Qu P
Molecules; 2022 Dec; 27(24):. PubMed ID: 36558006
[TBL] [Abstract][Full Text] [Related]
10. MiR-149-3p promotes the cisplatin resistance and EMT in ovarian cancer through downregulating TIMP2 and CDKN1A.
Wang J; Liu L
J Ovarian Res; 2021 Nov; 14(1):165. PubMed ID: 34798882
[TBL] [Abstract][Full Text] [Related]
11. Platinum-induced mitochondrial OXPHOS contributes to cancer stem cell enrichment in ovarian cancer.
Sriramkumar S; Sood R; Huntington TD; Ghobashi AH; Vuong TT; Metcalfe TX; Wang W; Nephew KP; O'Hagan HM
J Transl Med; 2022 May; 20(1):246. PubMed ID: 35641987
[TBL] [Abstract][Full Text] [Related]
12. Shikonin and cisplatin synergistically overcome cisplatin resistance of ovarian cancer by inducing ferroptosis via upregulation of HMOX1 to promote Fe
Ni M; Zhou J; Zhu Z; Xu Q; Yin Z; Wang Y; Zheng Z; Zhao H
Phytomedicine; 2023 Apr; 112():154701. PubMed ID: 36773431
[TBL] [Abstract][Full Text] [Related]
13. MiR-30a-5p Enhances Cisplatin Sensitivity by Downregulating RIF1 in Ovarian Cancer.
Yao W; Wang Y; Huang M; Zhou J; Zheng R; Jin C; Zhang Y
Ann Clin Lab Sci; 2023 May; 53(3):418-426. PubMed ID: 37437929
[TBL] [Abstract][Full Text] [Related]
14. Dinaciclib as an effective pan-cyclin dependent kinase inhibitor in platinum resistant ovarian cancer.
Howard D; James D; Garcia-Parra J; Pan-Castillo B; Worthington J; Williams N; Coombes Z; Rees SC; Lutchman-Singh K; Francis LW; Rees P; Margarit L; Conlan RS; Gonzalez D
Front Oncol; 2022; 12():1014280. PubMed ID: 36505806
[TBL] [Abstract][Full Text] [Related]
15. Novel role of lncRNA CHRF in cisplatin resistance of ovarian cancer is mediated by miR-10b induced EMT and STAT3 signaling.
Tan WX; Sun G; Shangguan MY; Gui Z; Bao Y; Li YF; Jia ZH
Sci Rep; 2020 Sep; 10(1):14768. PubMed ID: 32901049
[TBL] [Abstract][Full Text] [Related]
16. DMBT1 suppresses cell proliferation, migration and invasion in ovarian cancer and enhances sensitivity to cisplatin through galectin-3/PI3k/Akt pathway.
Ma N; Zhao Y
Cell Biochem Funct; 2020 Aug; 38(6):801-809. PubMed ID: 32424818
[TBL] [Abstract][Full Text] [Related]
17. The Anthelmintic Drug Niclosamide Inhibits the Proliferative Activity of Human Osteosarcoma Cells by Targeting Multiple Signal Pathways.
Liao Z; Nan G; Yan Z; Zeng L; Deng Y; Ye J; Zhang Z; Qiao M; Li R; Denduluri S; Wang J; Wei Q; Geng N; Zhao L; Lu S; Wang X; Zhou G; Luu HH; Haydon RC; He TC; Wang Z
Curr Cancer Drug Targets; 2015; 15(8):726-38. PubMed ID: 26118906
[TBL] [Abstract][Full Text] [Related]
18. Niclosamide Exhibits Potent Anticancer Activity and Synergizes with Sorafenib in Human Renal Cell Cancer Cells.
Yu X; Liu F; Zeng L; He F; Zhang R; Yan S; Zeng Z; Shu Y; Zhao C; Wu X; Lei J; Zhang W; Yang C; Wu K; Wu Y; An L; Huang S; Ji X; Gong C; Yuan C; Zhang L; Feng Y; Huang B; Liu W; Zhang B; Dai Z; Wang X; Liu B; Haydon RC; Luu HH; Gan H; He TC; Chen L
Cell Physiol Biochem; 2018; 47(3):957-971. PubMed ID: 29843133
[TBL] [Abstract][Full Text] [Related]
19. Isoalantolactone Suppresses Glycolysis and Resensitizes Cisplatin-Based Chemotherapy in Cisplatin-Resistant Ovarian Cancer Cells.
Chun J
Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569773
[TBL] [Abstract][Full Text] [Related]
20. Metformin anticancer: Reverses tumor hypoxia induced by bevacizumab and reduces the expression of cancer stem cell markers CD44/CD117 in human ovarian cancer SKOV3 cells.
Fan Y; Cheng H; Liu Y; Liu S; Lowe S; Li Y; Bentley R; King B; Tuason JPW; Zhou Q; Sun C; Zhang H
Front Pharmacol; 2022; 13():955984. PubMed ID: 36046821
[No Abstract] [Full Text] [Related]
[Next] [New Search]
